SCHEMBL7650160

SCHEMBL7650160

CCN(CC)S(=O)(=O)c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 5/20 0.66
LMNA P02545 3/20 0.66
SMN1; SMN2 Q16637 2/20 0.66
CA12 O43570 4/20 0.62
CA9 Q16790 4/20 0.62
CA1 P00915 3/20 0.62
CA2 P00918 3/20 0.62
CA3 P07451 3/20 0.62
CA4 P22748 3/20 0.62
CA6 P23280 3/20 0.62
CA5A P35218 3/20 0.62
CA7 P43166 3/20 0.62
CA13 Q8N1Q1 3/20 0.62
CA14 Q9ULX7 3/20 0.62
CA5B Q9Y2D0 3/20 0.62
VCAM1 P19320 1/20 0.59
NPC1 O15118 1/20 0.59
RAB9A P51151 1/20 0.59
KMT2A Q03164 4/20 0.54
POLB P06746 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1471666 0.90 SMN1; SMN2 (0.78) HTTLMNASMN1; SMN2CA12CA9
SCHEMBL27313733 0.87 CA12 (0.53) HTTLMNASMN1; SMN2CA12CA9
SCHEMBL7543999 0.87 HTT (0.51) HTTLMNASMN1; SMN2CA12CA9
SCHEMBL28031906 0.87 CA12 (0.69) HTTLMNASMN1; SMN2CA12CA9
SCHEMBL20828073 0.86 CA12 (0.53) HTTLMNASMN1; SMN2CA12CA9
SCHEMBL18029396 0.85 CA9 (0.64) HTTLMNASMN1; SMN2CA12CA9
SCHEMBL14228900 0.84 CA12 (0.62) HTTLMNASMN1; SMN2CA12CA9
SCHEMBL11498983 0.84 CA9 (0.57) HTTLMNASMN1; SMN2CA12CA9
SCHEMBL14229664 0.82 CA12 (0.67) HTTLMNASMN1; SMN2CA12CA9
SCHEMBL4589706 0.81 SMN1; SMN2 (0.63) HTTLMNASMN1; SMN2CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4719413-A1 INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF Animol Discovery, Inc. (US) 2026-04-08 EP disclosed
US-20260092070-A1 INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF ANIMOL DISCOVERY INC (US) 2026-04-02 US disclosed
WO-2024246837-A1 INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF ANIMOL DISCOVERY, INC. (US) 2024-12-05 WO disclosed
EP-2994457-B1 RADIOMITIGATING PHARMACEUTICAL FORMULATIONS UNIV CALIFORNIA (US) 2021-01-06 EP disclosed
US-20180162827-A1 RADIOMITIGATING PHARMACEUTICAL FORMULATIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2018-06-14 US disclosed
US-9840483-B2 Radiomitigating pharmaceutical formulations THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-12-12 US disclosed
US-9783515-B2 Radiomitigating pharmaceutical formulations THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-10-10 US disclosed
US-9783515-B2 Radiomitigating pharmaceutical formulations THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-10-10 US disclosed
US-9783515-B2 Radiomitigating pharmaceutical formulations THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-10-10 US disclosed
US-20160221976-A1 RADIOMITIGATING PHARMACEUTICAL FORMULATIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2016-08-04 US disclosed
US-20160221976-A1 RADIOMITIGATING PHARMACEUTICAL FORMULATIONS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2016-08-04 US disclosed
US-20160090369-A1 RADIOMITIGATING PHARMACEUTICAL FORMULATIONS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-03-31 US disclosed
US-6407120-B1 ADMINISTERING PYRIDINYLACETAMIDE OR PHENYLACETAMIDE DERIVATIVE TO TREAT CARDIOVASCULAR, EATING, SEXUAL, BRAIN, NERVOUS SYSTEM, GASTROINTESTINAL, UROGENITAL, PSYCHOLOGICAL, AND RESPIRATORY SYSTEM DISORDERS PFIZER INC. 2002-06-18 US disclosed
EP-1033366-A2 Amide derivatives useful as Neuropeptide Y (NPY) antagonists Pfizer Products Inc. (US) 2000-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160221976-A1 RADIOMITIGATING PHARMACEUTICAL FORMULATIONS LIPG, SGMS2, SGMS1 HTT 4155/4885LMNA 1838/4885SMN1; SMN2 3642/4885
US-20180162827-A1 RADIOMITIGATING PHARMACEUTICAL FORMULATIONS LIPG, SGMS2, SGMS1 HTT 4155/4885LMNA 1838/4885SMN1; SMN2 3642/4885
US-20260092070-A1 INHIBITORS OF CANINE JANUS KINASE AND USES THEREOF JAK1, JAK3, JAK2 HTT 3902/4885LMNA 4444/4885SMN1; SMN2 4009/4885
US-20160090369-A1 RADIOMITIGATING PHARMACEUTICAL FORMULATIONS LIPG, SGMS2, SGMS1 HTT 4155/4885LMNA 1838/4885SMN1; SMN2 3642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.